PE-041 Impact associated with pertuzumab and trastuzumab SC and IV formulations utilization in metastatic HER2- positive breast cancer patients treated in SUS

PE-041 Impact associated with pertuzumab and trastuzumab SC and IV formulations utilization in metastatic HER2- positive breast cancer patients treated in SUS

Introduction: Current gold standard therapy for metastatic breast cancer (mBC) HER2-positive patients – double blockage with pertuzumab and trastuzumab (P+T) – is available in the Sistema Único de Saúde (SUS) as intravenous (IV) formulations. Despite important clinical and economic benefits that th...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabel Monteiro, Florine Cordeiro, Tamie Martins, Clarissa Medeiros
Format: Article
Language:English
Published: Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia 2025-03-01
Series:Jornal de Assistência Farmacêutica e Farmacoeconomia
Subjects:
Breast cancer
Subcutaneous
Intravenous
Economics
Online Access:https://www.ojs.jaff.org.br/ojs/index.php/jaff/article/view/1152
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ojs.jaff.org.br/ojs/index.php/jaff/article/view/1152

Similar Items